百令胶囊联合头孢哌酮舒巴坦治疗慢性支气管炎急性发作期的临床研究

目的探讨百令胶囊联合头孢哌酮舒巴坦治疗慢性支气管炎急性发作期的临床效果。方法选择2016年10月—2017年10月在信阳市中心医院治疗的慢性支气管炎急性发作期患者154例,随机分成对照组(77例)和治疗组(77例)。对照组患者静脉滴注注射用头孢哌酮钠舒巴坦钠,4.0 g加入250 mL生理盐水,2次/d。治疗组患者在对照组基础上口服百令胶囊,10粒/次,3次/d。两组患者均连续治疗15d。观察两组患者临床疗效,同时比较治疗前后两组患者血清指标和圣乔治呼吸问卷(SGRQ)评分、临床症状消失时间和不良反应情况。结果治疗后,对照组临床有效率为84.42%,显著低于治疗组的96.10%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者血清C反应蛋白(CRP)水平和SGRQ评分较治疗前显著降低(P0.05),且治疗组患者血清CRP水平和SGRQ评分比对照组降低更明显(P0.05)。治疗后,治疗组患者咳嗽消失时间、X线炎症消失时间均显著早于对照组(P0.05)。治疗期间,治疗组药物不良反应发生率为2.60%,显著低于对照组的12.99%,两组比较差异具有统计学意义(P0.05)。结论百令胶囊联合头孢哌酮舒巴坦治疗慢性支气管炎急性发作期不良反应少,疗效确切,具有一定的临床应用价值。

Clinical study on Bailing Capsules combined with cefoperazone and sulbactam in treatment of acute exacerbation of chronic bronchitis

Objective To explore the clinical effect of Bailing Capsules combined with cefoperazone and sulbactam in treatment of acute exacerbation of chronic bronchitis. Methods Patients (154 cases) with acute exacerbation of chronic bronchitis in Xinyang Central Hospital from October 2016 to October 2017 were randomly divided into control (77 cases) and treatment (77 cases) groups. Patients in the control group were iv administered with Cefoperazone Sodium and Sulbactam Sodium for injection, 4.0 g added into normal saline 250 mL, twice daily. Patients in the treatment group were po administered with Bailing Capsules on the basis of the control group, 10 grains/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical efficacy was evaluated, and the serum indexes, SGRQ scores, the disappearance time of clinical symptoms and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 84.42%, which was significantly lower than 96.10% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the serum CRP levels and SGRQ scores in two groups were significantly decreased (P<0.05), and the serum CRP levels and SGRQ scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the disappearance time of cough and X-ray inflammation in the treatment group was significantly earlier than that in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 2.60%, which was significantly lower than 12.99% in the control group, with significant difference between two groups (P<0.05). Conclusion Bailing Capsules combined with cefoperazone and sulbactam in treatment of acute exacerbation of chronic bronchitis has fewer adverse reactions and definite curative effect, which has a certain clinical application value.